Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Net Income: 2014-2025

Historic Net Income for Zevra Therapeutics (ZVRA) over the last 11 years, with Sep 2025 value amounting to -$544,000.

  • Zevra Therapeutics' Net Income rose 98.36% to -$544,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 139.40%. This contributed to the annual value of -$105.5 million for FY2024, which is 129.13% down from last year.
  • As of Q3 2025, Zevra Therapeutics' Net Income stood at -$544,000, which was down 100.73% from $74.7 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Net Income ranged from a high of $74.7 million in Q2 2025 and a low of -$35.7 million during Q4 2024.
  • Its 3-year average for Net Income is -$7.3 million, with a median of -$13.2 million in 2023.
  • Its Net Income has fluctuated over the past 5 years, first spiked by 622.12% in 2021, then plummeted by 674.39% in 2024.
  • Quarterly analysis of 5 years shows Zevra Therapeutics' Net Income stood at -$2.7 million in 2021, then soared by 368.41% to $7.3 million in 2022, then plummeted by 374.18% to -$19.9 million in 2023, then plummeted by 79.67% to -$35.7 million in 2024, then skyrocketed by 98.36% to -$544,000 in 2025.
  • Its Net Income stands at -$544,000 for Q3 2025, versus $74.7 million for Q2 2025 and -$3.1 million for Q1 2025.